We are experts in developing medicines for difficult-to-treat patient groups
Therakind is a specialty pharmaceutical company focused on developing niche medicines in difficult-to-treat markets including paediatric and geriatric patient groups. We have developed and obtained marketing authorisations for three paediatric products, with Jylamvo, our European approved oral methotrexate solution for treating rheumatological and dermatological diseases and acute lymphoblastic leukaemia, also licensed for adults.
Our proprietary pipeline is focused on improving medicine adherence through more patient friendly dosing options and we have a strong track record in the research and development of innovative medicines and drug delivery systems designed specifically to take into account the pharmacodynamics and pharmacokinetics of difficult-to-treat patient groups.
DriDose®, our intranasal device for the delivery of a dry powder drug formulation is available for co-development.